Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Leuk Lymphoma
    April 2024
  1. SANCHO JM, Abrisqueta P, Kumar A, Cordoba R, et al
    Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL?112).
    Leuk Lymphoma. 2024 Apr 10:1-11. doi: 10.1080/10428194.2024.2331626.
    >> Share

  2. SCHAFF L, Nayak L, Grommes C
    Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Leuk Lymphoma. 2024 Apr 10:1-13. doi: 10.1080/10428194.2024.2333985.
    >> Share

  3. CUI C, Feng C, Rosenthal N, Wade SW, et al
    Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States.
    Leuk Lymphoma. 2024 Apr 3:1-10. doi: 10.1080/10428194.2024.2331084.
    >> Share

  4. ATTYGALLE AD, Chan JKC, Coupland SE, Du MQ, et al
    The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors - an overview and update.
    Leuk Lymphoma. 2024;65:413-429.
    >> Share

  5. ATALLAH-YUNES SA, Khurana A, Maurer M
    Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.
    Leuk Lymphoma. 2024;65:430-439.
    >> Share

  6. SONG Y, Li J, Zhou K, Ke X, et al
    Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024 Apr 1:1-6. doi: 10.1080/10428194.2024.2310141.
    >> Share

    March 2024
  7. RYU TIGER YK, Jain S, Barta SK, Tolu S, et al
    Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 22:1-10. doi: 10.1080/10428194.2024.2329996.
    >> Share

  8. TZIONI MM, Clipson A, Chen Z, Cucco F, et al
    Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 22:1-5. doi: 10.1080/10428194.2024.2332508.
    >> Share

  9. GAO LR, Wang X, Wu Y, Feng XL, et al
    Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2024 Mar 20:1-12. doi: 10.1080/10428194.2024.2329328.
    >> Share

  10. ITCHAKI G, Jarhovsky O, Castillo JJ, Hassan H, et al
    Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.
    Leuk Lymphoma. 2024 Mar 19:1-7. doi: 10.1080/10428194.2024.2332499.
    >> Share

  11. LI L, Yang W, Pan Y, Ye R, et al
    Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 18:1-16. doi: 10.1080/10428194.2024.2328227.
    >> Share

  12. RAMALINGAM TR
    Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma.
    Leuk Lymphoma. 2024 Mar 14:1-2. doi: 10.1080/10428194.2024.2330707.
    >> Share

  13. GORDON MJ, Dubois S, Bryant B, Ng S, et al
    A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 9:1-4. doi: 10.1080/10428194.2024.2326847.
    >> Share

  14. HILL BT, Chen Y, Jagadeesh D, Dean R, et al
    Lenalidomide, rituximab (R(2)), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
    Leuk Lymphoma. 2024 Mar 8:1-6. doi: 10.1080/10428194.2024.2325636.
    >> Share

  15. AKINGBEMI W, Kurtz G, Yegya-Raman N, Plastaras JP, et al
    Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
    Leuk Lymphoma. 2024 Mar 7:1-4. doi: 10.1080/10428194.2024.2322033.
    >> Share

  16. LEROY M, Deramoudt L, Pinturaud M, Demaret J, et al
    A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
    Leuk Lymphoma. 2024 Mar 5:1-4. doi: 10.1080/10428194.2024.2325188.
    >> Share

  17. BRAUNSTEIN Z, Waller A, Dotson E, McLaughlin E, et al
    Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.
    Leuk Lymphoma. 2024;65:301-311.
    >> Share

    February 2024
  18. MINSON A, Dickinson M
    Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2024 Feb 29:1-2. doi: 10.1080/10428194.2024.2320833.
    >> Share

  19. WEI C, Zhai F, Jia C, Zhang W, et al
    Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma.
    Leuk Lymphoma. 2024 Feb 22:1-4. doi: 10.1080/10428194.2024.2316252.
    >> Share

  20. TASHAKORI M, Medeiros LJ
    Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms.
    Leuk Lymphoma. 2024 Feb 21:1-5. doi: 10.1080/10428194.2024.2319691.
    >> Share

  21. NEMEC R, Scherrer-Crosbie M, Abramson JS, Redd R, et al
    Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
    Leuk Lymphoma. 2024 Feb 21:1-6. doi: 10.1080/10428194.2024.2317343.
    >> Share

  22. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    >> Share

  23. OSTERGAARD S, Schejbel L, Breinholt MF, Pedersen MO, et al
    Mutational landscape in Waldenstrom macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
    Leuk Lymphoma. 2024 Feb 10:1-10. doi: 10.1080/10428194.2024.2313623.
    >> Share

  24. MAGRO CM, Kalomeris T, Shreve CR, Geyer JT, et al
    Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration.
    Leuk Lymphoma. 2024 Feb 5:1-9. doi: 10.1080/10428194.2024.2310139.
    >> Share

  25. GRIEVE C, Joseph A, Drullinsky P, Zelenetz AD, et al
    Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024;65:235-241.
    >> Share

    January 2024
  26. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    >> Share

  27. ARYA S, Mozessohn L, Gong I, Faught N, et al
    The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study.
    Leuk Lymphoma. 2024 Jan 24:1-9. doi: 10.1080/10428194.2024.2306463.
    >> Share

  28. LIONEL AC, Gurumurthi A, Fetooh A, Eldaya R, et al
    Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2024 Jan 22:1-5. doi: 10.1080/10428194.2024.2304622.
    >> Share

  29. GRAVENMIER C, Shah B, Hussaini M, Zhang L, et al
    Chimeric antigen receptor T-cells might unmask transdifferentiated histiocytic sarcoma during diffuse large B-cell lymphoma treatment.
    Leuk Lymphoma. 2024 Jan 19:1-5. doi: 10.1080/10428194.2023.2301038.
    >> Share

  30. JIN Q, Jiang H, Yue N, Zhang L, et al
    The prognostic value of CD8(+) CTLs, CD163(+) TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma.
    Leuk Lymphoma. 2024 Jan 10:1-9. doi: 10.1080/10428194.2023.2296364.
    >> Share

  31. LAORUANGROJ C, Atherton PJ, Wiseman GA, Ansell S, et al
    The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
    Leuk Lymphoma. 2024 Jan 8:1-6. doi: 10.1080/10428194.2023.2295792.
    >> Share

  32. DICKINSON M, Martinez-Lopez J, Jousseaume E, Yang H, et al
    Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
    Leuk Lymphoma. 2024 Jan 5:1-10. doi: 10.1080/10428194.2023.2289854.
    >> Share

  33. VIVIANI S, Vanazzi A, Frassoni S, Rusconi C, et al
    High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
    Leuk Lymphoma. 2024 Jan 2:1-12. doi: 10.1080/10428194.2023.2298273.
    >> Share

  34. GORDON ER, Kwinta BD, Schreidah CM, Fahmy LM, et al
    Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes.
    Leuk Lymphoma. 2024;65:48-54.
    >> Share

  35. RIVERA-FRANCIA VM, Failoc-Rojas VE, Villacorta-Carranza R, Leon Garrido-Lecca A, et al
    Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
    Leuk Lymphoma. 2024;65:37-47.
    >> Share

    December 2023
  36. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
    Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.
    Leuk Lymphoma. 2023 Dec 22:1-4. doi: 10.1080/10428194.2023.2296361.
    >> Share

  37. KANEDA Y, Kanemura N, Nakamura N, Ikoma Y, et al
    The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2023 Dec 20:1-7. doi: 10.1080/10428194.2023.2295787.
    >> Share

  38. KUIPERS MT, Spanjaart AM, Bonifazi F, diBlasi R, et al
    Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
    Leuk Lymphoma. 2023 Dec 9:1-4. doi: 10.1080/10428194.2023.2288804.
    >> Share

  39. KAWASAKI N, Tomita M, Yamashita-Kashima Y, Yoshimura Y, et al
    Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
    Leuk Lymphoma. 2023;64:1938-1948.
    >> Share

  40. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
    Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
    Leuk Lymphoma. 2023;64:2333-2337.
    >> Share

  41. REYNOLDS G, Anderson MA, Thursky K, Teh BW, et al
    Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis.
    Leuk Lymphoma. 2023;64:2057-2070.
    >> Share

  42. PENA J, Cull D, Strowd LC, Vaidya R, et al
    Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides.
    Leuk Lymphoma. 2023;64:2202-2207.
    >> Share

    November 2023
  43. CHOHAN KL, Bansal R, Hathcock MA, Paludo J, et al
    Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
    Leuk Lymphoma. 2023 Nov 30:1-5. doi: 10.1080/10428194.2023.2285236.
    >> Share

  44. ZHONG Q, Liu Y, Wu Y, Liu X, et al
    Impact of age on long-term relative survival benefit of radiotherapy for early-stage grade I-II follicular lymphoma from the SEER database (2000-2015).
    Leuk Lymphoma. 2023 Nov 21:1-11. doi: 10.1080/10428194.2023.2283296.
    >> Share

  45. FOUILLET L, Daguenet E, Tavernier E, Ghesquieres H, et al
    Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.
    Leuk Lymphoma. 2023 Nov 15:1-5. doi: 10.1080/10428194.2023.2281270.
    >> Share

  46. PACHECO JM, Forchhammer S, Otto F, Fend F, et al
    Primary cutaneous anaplastic large cell lymphoma with DUSP22-rearrangement presenting as a mimicker of mycosis fungoides: a case report and review of the literature.
    Leuk Lymphoma. 2023 Nov 7:1-5. doi: 10.1080/10428194.2023.2276678.
    >> Share

  47. NEWSAM AD, Coughlin CA, Trabolsi A, Schatz JH, et al
    Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2258244.
    >> Share

  48. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
    Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
    Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
    >> Share

  49. DUAN Y, Gao H, Zhou C, Jin L, et al
    Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China.
    Leuk Lymphoma. 2023 Nov 2:1-6. doi: 10.1080/10428194.2023.2263120.
    >> Share

    October 2023
  50. VILLENEUVE PJ, Harris SA
    Re: exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Oct 30:1-3. doi: 10.1080/10428194.2023.2275529.
    >> Share

  51. KUMAR AJ, Pearson LK, Wong JB, Friedberg JW, et al
    Understanding treatment decisions for Hodgkin lymphoma: a qualitative study.
    Leuk Lymphoma. 2023 Oct 28:1-9. doi: 10.1080/10428194.2023.2256913.
    >> Share

  52. WOOTEN SV, Amini B, Roth M, Leung CH, et al
    Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report.
    Leuk Lymphoma. 2023 Oct 25:1-7. doi: 10.1080/10428194.2023.2273747.
    >> Share

  53. ASMUSSEN A, Quintanilla-Martinez L, Larsen M, Fagerberg C, et al
    Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case.
    Leuk Lymphoma. 2023 Oct 23:1-5. doi: 10.1080/10428194.2023.2264425.
    >> Share

  54. HESS G, Dreyling M, Oberic L, Gine E, et al
    Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 Oct 16:1-12. doi: 10.1080/10428194.2023.2268228.
    >> Share

  55. MCGOUGH SF, Shamas N, Wang J, Jaber M, et al
    Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
    Leuk Lymphoma. 2023 Oct 15:1-10. doi: 10.1080/10428194.2023.2262066.
    >> Share

  56. GRIBBIN C, Chen J, Martin P, Ruan J, et al
    Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
    Leuk Lymphoma. 2023 Oct 6:1-13. doi: 10.1080/10428194.2023.2264430.
    >> Share

  57. STUVER R, Vardhana SA, Bedmutha A, Chan KK, et al
    Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.
    Leuk Lymphoma. 2023 Oct 5:1-3. doi: 10.1080/10428194.2023.2262641.
    >> Share

  58. IKEDA D, Oura M, Uehara A, Tabata R, et al
    Efficacy of darinaparsin for EBV-associated B-cell lymphoma in a heavily treated elderly patient with angioimmunoblastic T-cell lymphoma: a case report.
    Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2265001.
    >> Share

  59. ZAK T, Santana-Santos L, Gao J, Behdad A, et al
    Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma.
    Leuk Lymphoma. 2023 Oct 5:1-11. doi: 10.1080/10428194.2023.2264429.
    >> Share

    September 2023
  60. IP A, Petrillo A, Della Pia A, Lee GG, et al
    Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 Sep 23:1-11. doi: 10.1080/10428194.2023.2259528.
    >> Share

  61. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
    Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
    >> Share

  62. ABDULRAHMAN N, Leo R, Boumenar HA, Ahmad F, et al
    Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
    Leuk Lymphoma. 2023 Sep 14:1-13. doi: 10.1080/10428194.2023.2256909.
    >> Share

  63. FRERET ME, Tringale KR, Boe L, Imber BS, et al
    Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
    Leuk Lymphoma. 2023 Sep 14:1-7. doi: 10.1080/10428194.2023.2255706.
    >> Share

  64. GORDON MJ, Duan Z, Zhao H, Nastoupil L, et al
    Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
    Leuk Lymphoma. 2023 Sep 14:1-11. doi: 10.1080/10428194.2023.2256908.
    >> Share

  65. DAHI PB, Kenny S, Flynn J, Devlin SM, et al
    Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Sep 10:1-7. doi: 10.1080/10428194.2023.2256912.
    >> Share

  66. LEICH E, Brodtkorb M, Schmidt T, Altenbuchinger M, et al
    Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.
    Leuk Lymphoma. 2023 Sep 8:1-11. doi: 10.1080/10428194.2023.2240462.
    >> Share

  67. GOENKA L, Kumar SM, Essakky S, Rajasulochana SR, et al
    Cost-effectiveness of response-adapted therapy (RAT) for advanced Hodgkin's Lymphoma compared with conventional treatment in India: a Markov-model based analysis.
    Leuk Lymphoma. 2023 Sep 5:1-7. doi: 10.1080/10428194.2023.2249154.
    >> Share

  68. YAN Y, Qu S, Liu J, Li C, et al
    Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement.
    Leuk Lymphoma. 2023;64:1605-1610.
    >> Share

    August 2023
  69. ASSIS-MENDONCA GR, Campos LG, Delamain MT, de Brito ABC, et al
    Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2023 Aug 30:1-13. doi: 10.1080/10428194.2023.2248330.
    >> Share

  70. MELLGARD G, Stoffel E, Michel A, Iqbal F, et al
    Hypereosinophilic syndrome with leptomeningeal involvement: a not-so-classical case report of classical Hodgkin Lymphoma.
    Leuk Lymphoma. 2023 Aug 28:1-6. doi: 10.1080/10428194.2023.2252124.
    >> Share

  71. OBAMA K
    Why is red cell distribution width a prognostic factor for peripheral T-cell lymphoma?
    Leuk Lymphoma. 2023 Aug 25:1-2. doi: 10.1080/10428194.2023.2249156.
    >> Share

  72. VELY A, Couturier MA, Delepine P, Le Calloch R, et al
    Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Aug 24:1-10. doi: 10.1080/10428194.2023.2251073.
    >> Share

  73. RAJENDRA A, Sengar M, Bonda VNA, Jain H, et al
    Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL).
    Leuk Lymphoma. 2023 Aug 21:1-13. doi: 10.1080/10428194.2023.2244101.
    >> Share

  74. PARK YG, Cho H, Kim S, Lee K, et al
    Prognostic significance of 25-hydroxyvitamin D levels in patients with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2023 Aug 12:1-7. doi: 10.1080/10428194.2023.2243530.
    >> Share

  75. MA H, Marchi E, O'Connor OA, Lue JK, et al
    Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experience.
    Leuk Lymphoma. 2023 Aug 11:1-7. doi: 10.1080/10428194.2023.2245513.
    >> Share

  76. FRIED S, Shkury E, Itzhaki O, Sdayoor I, et al
    Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma.
    Leuk Lymphoma. 2023 Aug 11:1-8. doi: 10.1080/10428194.2023.2246611.
    >> Share

  77. KENKRE VP, Bradley K, Milton A, Burkholder JK, et al
    TCR-alpha/beta and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience.
    Leuk Lymphoma. 2023 Aug 10:1-5. doi: 10.1080/10428194.2023.2240918.
    >> Share

  78. MODEMANN F, Ahmadi P, von Kroge PH, Weidemann S, et al
    The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysis.
    Leuk Lymphoma. 2023 Aug 8:1-10. doi: 10.1080/10428194.2023.2240921.
    >> Share

  79. GONG IY, Aminilari M, Landego I, Hueniken K, et al
    Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
    Leuk Lymphoma. 2023 Aug 7:1-12. doi: 10.1080/10428194.2023.2234528.
    >> Share

  80. BECERRIL-RICO J, Delgado-Montes YA, Ortiz-Sanchez E
    Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Leuk Lymphoma. 2023 Aug 7:1-10. doi: 10.1080/10428194.2023.2243357.
    >> Share

  81. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.
    Leuk Lymphoma. 2023 Aug 2:1-9. doi: 10.1080/10428194.2023.2241095.
    >> Share

    July 2023
  82. SQUIRES P, Puckett J, Ryland KE, Kamal-Bahl S, et al
    Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
    Leuk Lymphoma. 2023 Jul 27:1-13. doi: 10.1080/10428194.2023.2234525.
    >> Share

  83. ASIMAKOPOULOS JV, Dolkiras F, Lakiotaki E, Rondogianni P, et al
    Prolonged 3-year spontaneous remission of diffuse large B-cell lymphoma upon withdrawal of infliximab and late relapse in a patient with psoriasis: a case report and review of the literature.
    Leuk Lymphoma. 2023 Jul 26:1-6. doi: 10.1080/10428194.2023.2232488.
    >> Share

  84. COLLET A, Attias P, Lacou M, Fieschi C, et al
    AA-type amyloidosis associated with lymphoma: a study of 19 cases including 5 new French cases and a systematic literature review.
    Leuk Lymphoma. 2023 Jul 26:1-7. doi: 10.1080/10428194.2023.2239971.
    >> Share

  85. RUSSLER-GERMAIN DA, Calhoun BR, Wu N, Watkins MP, et al
    FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV(max) as a predictive biomarker in frontline treatment of mantle cell lymphoma.
    Leuk Lymphoma. 2023 Jul 25:1-5. doi: 10.1080/10428194.2023.2239404.
    >> Share

  86. CHANG EWY, Yang VS, Ong SY, Kang HX, et al
    Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study.
    Leuk Lymphoma. 2023 Jul 21:1-10. doi: 10.1080/10428194.2023.2235043.
    >> Share

  87. RODRIGUES-FERNANDES CI, Martins-Chaves RR, Vitorio JG, Duarte-Andrade FF, et al
    The altered metabolic pathways of diffuse large B-cell lymphoma not otherwise specified.
    Leuk Lymphoma. 2023 Jul 18:1-11. doi: 10.1080/10428194.2023.2234523.
    >> Share

  88. CENCINI E, Sicuranza A, Fabbri A, Marzano C, et al
    The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study.
    Leuk Lymphoma. 2023 Jul 9:1-9. doi: 10.1080/10428194.2023.2232490.
    >> Share

    June 2023
  89. SHICHIJO T, Tatetsu H, Nosaka K, Higuchi Y, et al
    Robust prognostic value of histologic transformation in patients with early progression of follicular lymphoma.
    Leuk Lymphoma. 2023 Jun 30:1-5. doi: 10.1080/10428194.2023.2226429.
    >> Share

  90. LUTTWAK E, Noy A, Seshan V, Saltzman LA, et al
    The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.
    Leuk Lymphoma. 2023 Jun 29:1-3. doi: 10.1080/10428194.2023.2227749.
    >> Share

  91. ROZENTAL A, Jim HSL, Extermann M
    Treatment of older patients with mantle cell lymphoma in the era of novel agents.
    Leuk Lymphoma. 2023 Jun 26:1-13. doi: 10.1080/10428194.2023.2227748.
    >> Share

  92. WALLACE DS, Rowland C, Hill BT, Baran AM, et al
    Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 Jun 21:1-4. doi: 10.1080/10428194.2023.2223743.
    >> Share

  93. PUCKRIN R, Owen C, Street L, Perry S, et al
    Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma.
    Leuk Lymphoma. 2023 Jun 20:1-4. doi: 10.1080/10428194.2023.2226278.
    >> Share

  94. HERSBY DS, Schejbel L, Breinholt MF, Hogdall E, et al
    Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2023 Jun 16:1-9. doi: 10.1080/10428194.2023.2220454.
    >> Share

  95. GROMMES C, Pentsova E, Schaff LR, Nolan CP, et al
    Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma.
    Leuk Lymphoma. 2023 Jun 15:1-9. doi: 10.1080/10428194.2023.2223734.
    >> Share

  96. PARISI R, Cowen EA, Gu S, Dusza S, et al
    Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.
    Leuk Lymphoma. 2023 Jun 12:1-5. doi: 10.1080/10428194.2023.2221756.
    >> Share

  97. BANERJEE T, Newman M, Chen A, Maziarz RT, et al
    A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 Jun 7:1-4. doi: 10.1080/10428194.2023.2212098.
    >> Share

  98. SALIM R, Husby S, Winther Eskelund C, Scott DW, et al
    Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score.
    Leuk Lymphoma. 2023 Jun 1:1-10. doi: 10.1080/10428194.2023.2216819.
    >> Share

  99. TORKA P, Russell T, Mavis C, Gu J, et al
    AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.
    Leuk Lymphoma. 2023;64:1175-1185.
    >> Share

    May 2023
  100. BRAVO J, Baltasar Tello P, Gonzalez Garcia E, Rios Herranz E, et al
    Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
    Leuk Lymphoma. 2023 May 31:1-14. doi: 10.1080/10428194.2023.2216327.
    >> Share

  101. MARCHETTI M, Visco C
    Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 May 25:1-9. doi: 10.1080/10428194.2023.2215888.
    >> Share

  102. NICHOLS MM, Ondrejka SL, Patil S, Durkin L, et al
    Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP.
    Leuk Lymphoma. 2023 May 24:1-9. doi: 10.1080/10428194.2023.2214651.
    >> Share

  103. WAYE A, Thanh NX, Buckland T, Scott AN, et al
    Return on investment of the lymphoma diagnostic pathway implementation in Alberta, Canada.
    Leuk Lymphoma. 2023 May 12:1-9. doi: 10.1080/10428194.2023.2209232.
    >> Share

  104. GULBRANDSEN MS, Noding AS, Smeland KB, Eikeland SA, et al
    Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma.
    Leuk Lymphoma. 2023 May 5:1-12. doi: 10.1080/10428194.2023.2198053.
    >> Share

  105. CASTRO D, Valcarcel B, Runciman T, Huerta-Collado Y, et al
    The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study.
    Leuk Lymphoma. 2023 May 3:1-9. doi: 10.1080/10428194.2023.2205975.
    >> Share

  106. AGRAWAL P, David KA, Chen Z, Sundaram S, et al
    EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.
    Leuk Lymphoma. 2023;64:1026-1034.
    >> Share

    April 2023
  107. LI L, Zeng P, Yu L, Yang J, et al
    Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/beta-catenin and mTORC1 signaling.
    Leuk Lymphoma. 2023 Apr 24:1-10. doi: 10.1080/10428194.2023.2202291.
    >> Share

  108. PHILLIPS T, Migliaccio-Walle K, Yu KS, Bloudek B, et al
    Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
    Leuk Lymphoma. 2023 Apr 19:1-9. doi: 10.1080/10428194.2023.2193854.
    >> Share

  109. TAKAHASHI H, Natsumeda M, On J, Watanabe J, et al
    Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients.
    Leuk Lymphoma. 2023 Apr 18:1-4. doi: 10.1080/10428194.2023.2199895.
    >> Share

  110. NG WL, Wang Y, Bock AM, Jevremovic D, et al
    Review of management options for mantle cell lymphoma in pregnancy.
    Leuk Lymphoma. 2023 Apr 10:1-5. doi: 10.1080/10428194.2023.2196592.
    >> Share

  111. FISCHER L, Dreyling M
    Follicular lymphoma: an update on biology and optimal therapy.
    Leuk Lymphoma. 2023;64:761-775.
    >> Share

  112. ROBAK T, Kasprzak JD, Jesionek-Kupnicka D, Soin M, et al
    Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis.
    Leuk Lymphoma. 2023;64:884-888.
    >> Share

    March 2023
  113. EYRE TA, Hess LM, Sugihara T, He D, et al
    Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
    Leuk Lymphoma. 2023 Mar 29:1-12. doi: 10.1080/10428194.2023.2190436.
    >> Share

  114. SALVARIS RT, Allanson B, Cheah CY
    Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2023 Mar 24:1-5. doi: 10.1080/10428194.2023.2192316.
    >> Share

  115. HARDELL L, Carlberg M, Nordstrom M, Eriksson M, et al
    Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma- pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia.
    Leuk Lymphoma. 2023 Mar 20:1-8. doi: 10.1080/10428194.2023.2190434.
    >> Share

  116. JURADO R, Aren M, Sorigue M
    Should WE use flow cytometry to assess bone marrow involvement by lymphoma?
    Leuk Lymphoma. 2023 Mar 8:1-3. doi: 10.1080/10428194.2023.2186730.
    >> Share

  117. AL ZAKI A, McCurry D, Strati P
    CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy.
    Leuk Lymphoma. 2023 Mar 8:1-8. doi: 10.1080/10428194.2023.2185090.
    >> Share

  118. MAJUMDAR S, Sharma N, Sengar M, Thorat J, et al
    A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
    Leuk Lymphoma. 2023 Mar 8:1-11. doi: 10.1080/10428194.2023.2167491.
    >> Share

  119. SORTAIS C, Cordeil S, Bourbon E, Idlhaj M, et al
    Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.
    Leuk Lymphoma. 2023;64:707-711.
    >> Share

  120. BAGGIO D, Wellard C, Chung E, Talaulikar D, et al
    Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
    Leuk Lymphoma. 2023;64:621-627.
    >> Share

    February 2023
  121. XU W, Yang S, Zhou K, Pan L, et al
    Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
    Leuk Lymphoma. 2023 Feb 17:1-5. doi: 10.1080/10428194.2022.2164692.
    >> Share

  122. OWATARI S, Tokunaga M, Nakamura D, Uozumi K, et al
    A decrease in newly diagnosed patients with adult T-cell leukemia/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan.
    Leuk Lymphoma. 2023 Feb 10:1-9. doi: 10.1080/10428194.2023.2173524.
    >> Share

  123. VAN LE H, Van Naarden Braun K, Nowakowski GS, Sermer D, et al
    Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
    Leuk Lymphoma. 2023 Feb 8:1-13. doi: 10.1080/10428194.2022.2160200.
    >> Share

    January 2023
  124. LIN M, Wu X, Zhang L, Li L, et al
    Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
    >> Share

  125. GAUT D, Oliai C, Mead M
    Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series.
    Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.
    >> Share

  126. QUALLS D, Noy A, Straus D, Matasar M, et al
    Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
    Leuk Lymphoma. 2023 Jan 15:1-4. doi: 10.1080/10428194.2022.2164194.
    >> Share

  127. KALOYANNIDIS P, Al Zayer M, Al Darweesh M, Al Batran M, et al
    Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Jan 11:1-4. doi: 10.1080/10428194.2022.2164195.
    >> Share

  128. RUSCONI C, Visco C
    Putting the brain into mantle cell lymphoma.
    Leuk Lymphoma. 2023 Jan 2:1-2. doi: 10.1080/10428194.2022.2163171.
    >> Share

  129. AMAADOR K, Kersten MJ, Minnema MC, Vos JMI, et al
    Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Leuk Lymphoma. 2023;64:30-41.
    >> Share

    December 2022
  130. FRONTZEK F, Hailfinger S, Lenz G
    Plasmablastic lymphoma: from genetics to treatment.
    Leuk Lymphoma. 2022 Dec 28:1-9. doi: 10.1080/10428194.2022.2162341.
    >> Share

  131. SIMBA K, Mohamed Z, Opie JJ, Andera LF, et al
    The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Dec 23:1-8. doi: 10.1080/10428194.2022.2157214.
    >> Share

  132. PLUMPTRE IR, Said JT, Sun T, Larocca C, et al
    Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review.
    Leuk Lymphoma. 2022;63:2832-2846.
    >> Share

  133. BROGLIO K, Kostakoglu L, Ward C, Mattiello F, et al
    PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design.
    Leuk Lymphoma. 2022;63:2816-2831.
    >> Share

  134. WANG P, Xu L, Fan Y, Li B, et al
    EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
    Leuk Lymphoma. 2022;63:3370-3377.
    >> Share

  135. JOSHI U, Bhattarai A, Gaire S, Gill S, et al
    Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study.
    Leuk Lymphoma. 2022;63:3456-3461.
    >> Share

  136. MAJOR A, Wright R, Hlubocky FJ, Smith SM, et al
    Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance.
    Leuk Lymphoma. 2022;63:3331-3339.
    >> Share

  137. TERAO T, Tsushima T, Ikeda D, Fukumoto A, et al
    Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
    Leuk Lymphoma. 2022;63:3394-3401.
    >> Share

  138. FRIED S, Shouval R, Varda-Bloom N, Besser MJ, et al
    Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.
    Leuk Lymphoma. 2022;63:3385-3393.
    >> Share

    November 2022
  139. GU L, Oh Y, Smith MP, Kurtansky NR, et al
    The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma.
    Leuk Lymphoma. 2022 Nov 26:1-3. doi: 10.1080/10428194.2022.2131418.
    >> Share

  140. MULLIGAN SP, Opat S, Cheah CY, Kuss B, et al
    Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
    Leuk Lymphoma. 2022 Nov 24:1-7. doi: 10.1080/10428194.2022.2148220.
    >> Share

  141. MILLS GS, Di Ciaccio PR, Tang C, Chadwick V, et al
    Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study.
    Leuk Lymphoma. 2022 Nov 24:1-10. doi: 10.1080/10428194.2022.2148376.
    >> Share

  142. MCLAUGHLIN N, Wang Y, Witzig T, Villasboas J, et al
    Central nervous system involvement by mantle cell lymphoma.
    Leuk Lymphoma. 2022 Nov 23:1-7. doi: 10.1080/10428194.2022.2148211.
    >> Share

  143. YANG H, Bollu V, Lim S, Tesfaye M, et al
    Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database.
    Leuk Lymphoma. 2022 Nov 21:1-10. doi: 10.1080/10428194.2022.2147395.
    >> Share

  144. FENLON JB, Hutten RJ, Johnson SB, Hu B, et al
    Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era.
    Leuk Lymphoma. 2022 Nov 21:1-8. doi: 10.1080/10428194.2022.2148215.
    >> Share

  145. KURUVILLA J, Armand P, Hamadani M, Kline J, et al
    Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
    Leuk Lymphoma. 2022 Nov 18:1-10. doi: 10.1080/10428194.2022.2136956.
    >> Share

  146. KISERUD CE, Lockmer S, Baerug I, Dahl AA, et al
    Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma - a comparison with normative data.
    Leuk Lymphoma. 2022 Nov 7:1-7. doi: 10.1080/10428194.2022.2142050.
    >> Share

  147. TYRYSHKIN K, Moore A, Good D, Popov J, et al
    Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy.
    Leuk Lymphoma. 2022 Nov 6:1-11. doi: 10.1080/10428194.2022.2136968.
    >> Share

  148. SALVARIS RT, Cheah CY
    Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?
    Leuk Lymphoma. 2022 Nov 4:1-3. doi: 10.1080/10428194.2022.2142057.
    >> Share

  149. PARK E, Lee C, Park J, Liu J, et al
    Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
    Leuk Lymphoma. 2022 Nov 4:1-12. doi: 10.1080/10428194.2022.2140282.
    >> Share

  150. CORTESE MJ, Wei W, Cerdena S, Watkins MP, et al
    A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
    Leuk Lymphoma. 2022 Nov 2:1-12. doi: 10.1080/10428194.2022.2140281.
    >> Share

  151. LAURENGE A, Ursu R, Tabouret E, Harlay V, et al
    SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era.
    Leuk Lymphoma. 2022 Nov 1:1-4. doi: 10.1080/10428194.2022.2131420.
    >> Share

  152. WYSOCKA M, Jariwala N, Zhang K, Benoit B, et al
    TCF1 and Tox define different subsets of CD4 T cells in patients with Sezary syndrome.
    Leuk Lymphoma. 2022;63:2715-2718.
    >> Share

    October 2022
  153. LIPSCOMB J, Switchenko JM, Flowers CR, Gillespie TW, et al
    Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia.
    Leuk Lymphoma. 2022 Oct 28:1-10. doi: 10.1080/10428194.2022.2133539.
    >> Share

  154. SHAH NN, Castillo-Tokumori F, Whiting J, Boulware D, et al
    Frontline treatment approaches in TP53-aberrant mantle cell lymphoma.
    Leuk Lymphoma. 2022 Oct 27:1-4. doi: 10.1080/10428194.2022.2131407.
    >> Share

  155. MO SS, Cleveland J, Rubenstein JL
    Primary CNS lymphoma: update on molecular pathogenesis and therapy.
    Leuk Lymphoma. 2022 Oct 26:1-9. doi: 10.1080/10428194.2022.2133541.
    >> Share

  156. GARDENSWARTZ A, Mehta B, El-Mallawany NK, van de Ven C, et al
    Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, a
    Leuk Lymphoma. 2022 Oct 19:1-4. doi: 10.1080/10428194.2022.2133542.
    >> Share

  157. ARDISSON KORAT AV, Chiu YH, Bertrand KA, Zhang S, et al
    A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Oct 18:1-11. doi: 10.1080/10428194.2022.2131419.
    >> Share

  158. VERGOTE VKJ, Verhoef G, Janssens A, Woei-A-Jin FJSH, et al
    [(18)F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma.
    Leuk Lymphoma. 2022 Oct 12:1-10. doi: 10.1080/10428194.2022.2131415.
    >> Share

  159. IRIYAMA N, Miura K, Takahashi H, Nakagawa M, et al
    Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience.
    Leuk Lymphoma. 2022 Oct 12:1-7. doi: 10.1080/10428194.2022.2131426.
    >> Share

  160. MA G, Gao Y, Jing X, He C, et al
    Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
    Leuk Lymphoma. 2022 Oct 10:1-11. doi: 10.1080/10428194.2022.2131427.
    >> Share

  161. KOSYDAR S, Ansell SM
    Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse.
    Leuk Lymphoma. 2022 Oct 10:1-13. doi: 10.1080/10428194.2022.2131422.
    >> Share

  162. FERHANOGLU B, Kim TM, Karduss A, Brittain D, et al
    Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study.
    Leuk Lymphoma. 2022 Oct 6:1-14. doi: 10.1080/10428194.2022.2126281.
    >> Share

  163. PARSONS MW, Wada DA, Halwani AS, Tao R, et al
    Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study.
    Leuk Lymphoma. 2022;63:2428-2435.
    >> Share

    September 2022
  164. HWANG HS, Sung HJ, Kim MJ, Yoon DH, et al
    Extra copy number of BCL2 is correlated with increased BCL-2 protein expression and poor survival in diffuse large B-cell lymphoma treated with chemoimmunotherapy.
    Leuk Lymphoma. 2022 Sep 27:1-10. doi: 10.1080/10428194.2022.2113525.
    >> Share

  165. MANJI F, Bhella S, Kridel R, Kukreti V, et al
    Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma.
    Leuk Lymphoma. 2022 Sep 27:1-7. doi: 10.1080/10428194.2022.2123226.
    >> Share

  166. WANG W, Gehris BT, Mai B, Chen L, et al
    HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation.
    Leuk Lymphoma. 2022 Sep 26:1-4. doi: 10.1080/10428194.2022.2123233.
    >> Share

  167. LIU J, Wei J, Jiang X, Yu W, et al
    Prognostic effects of clinical parameters, genetic abnormalities, and subtypes in primary gastric diffuse large B-cell lymphoma: a cohort analysis of 146 patients.
    Leuk Lymphoma. 2022 Sep 23:1-8. doi: 10.1080/10428194.2022.2126279.
    >> Share

  168. ZIBARA V, Sen F, Scordo M, Falchi L, et al
    Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
    Leuk Lymphoma. 2022 Sep 18:1-4. doi: 10.1080/10428194.2022.2113528.
    >> Share

  169. ZDUNIAK A, Leveque E, Perdrix A, Etancelin P, et al
    Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
    Leuk Lymphoma. 2022 Sep 18:1-11. doi: 10.1080/10428194.2022.2123222.
    >> Share

  170. DABAJA BS, Ng AK
    Let us give our Hodgkin's lymphoma patients the radiation they need.
    Leuk Lymphoma. 2022 Sep 15:1-2. doi: 10.1080/10428194.2022.2123237.
    >> Share

  171. BEHDAD A, Schipma MJ, Ma S, Chen YH, et al
    Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10.
    Leuk Lymphoma. 2022 Sep 14:1-5. doi: 10.1080/10428194.2022.2123236.
    >> Share

  172. WATSON LR, Lew TE, Fox LC, Khot A, et al
    Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma.
    Leuk Lymphoma. 2022 Sep 7:1-5. doi: 10.1080/10428194.2022.2118537.
    >> Share

  173. PASVOLSKY O, Berger T, Geiger KR, Akirov A, et al
    Infectious complications and long-term outcomes in patients with diffuse large B-Cell lymphoma and diabetes mellitus.
    Leuk Lymphoma. 2022 Sep 6:1-7. doi: 10.1080/10428194.2022.2118526.
    >> Share

  174. NOLAN J, Murphy C, Dinneen K, Lee G, et al
    p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.
    Leuk Lymphoma. 2022 Sep 5:1-4. doi: 10.1080/10428194.2022.2118529.
    >> Share

  175. OLUWOLE OO, Chen JMH, Chan K, Patel AR, et al
    Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
    Leuk Lymphoma. 2022 Sep 1:1-11. doi: 10.1080/10428194.2022.2113526.
    >> Share

  176. KATZ DA, Morris JD, Chu MP, David KA, et al
    Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
    Leuk Lymphoma. 2022;63:2063-2073.
    >> Share

  177. FERRAD M, Ghazzaui N, Issaoui H, Drouineau E, et al
    Homozygous iMycCalpha transgenic mice as a model of plasma B-cell lymphomas.
    Leuk Lymphoma. 2022;63:2114-2125.
    >> Share

  178. MARTINI DJ, Goyal S, Switchenko JM, Lechowicz MJ, et al
    African American and Caucasian patients with Sezary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
    Leuk Lymphoma. 2022;63:2094-2101.
    >> Share

    August 2022
  179. STAMATOULLAS A, Ghesquieres H, Feugier P, Andre M, et al
    Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
    Leuk Lymphoma. 2022 Aug 17:1-9. doi: 10.1080/10428194.2022.2107204.
    >> Share

  180. KUMAR A, Casulo C, Joffe E, Moskowitz C, et al
    Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
    Leuk Lymphoma. 2022 Aug 16:1-8. doi: 10.1080/10428194.2022.2109155.
    >> Share

  181. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    >> Share

  182. CHOHAN KL, Ansell SM
    The broader prospects for bispecifics in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Aug 3:1-3. doi: 10.1080/10428194.2022.2107205.
    >> Share

  183. SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
    Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
    >> Share

  184. HUGHES MS, Sterling CH, Varadhan R, Ambinder RF, et al
    Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study.
    Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105330.
    >> Share

  185. SERRANO LOPEZ J, Jimenez-Jimenez C, Chutipongtanate S, Serrano J, et al
    High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies.
    Leuk Lymphoma. 2022;63:1861-1870.
    >> Share

    July 2022
  186. WEIL CR, Parsons MJ, Hutten RJ, Lew FH, et al
    Patterns of care and outcomes of early stage I-II Hodgkin lymphoma treated with or without radiation therapy.
    Leuk Lymphoma. 2022 Jul 29:1-11. doi: 10.1080/10428194.2022.2105325.
    >> Share

  187. DAVIDSON MB, Rice A, Stewart D, Owen C, et al
    Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study.
    Leuk Lymphoma. 2022 Jul 25:1-4. doi: 10.1080/10428194.2022.2102620.
    >> Share

  188. GUAN T, Lo M, Young R, Ai W, et al
    Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.
    Leuk Lymphoma. 2022 Jul 25:1-4. doi: 10.1080/10428194.2022.2100369.
    >> Share

  189. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.
    >> Share

  190. SEIDEL S, Kowalski T, Nilius-Eliliwi V, Schroers R, et al
    Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients >/=80 years treated with high-dose methotrexate-based chemotherapy.
    Leuk Lymphoma. 2022 Jul 20:1-7. doi: 10.1080/10428194.2022.2100371.
    >> Share

  191. ON S, Chang A
    Treatment of lymphoma with rituximab and chemotherapy during pregnancy.
    Leuk Lymphoma. 2022 Jul 20:1-8. doi: 10.1080/10428194.2022.2100368.
    >> Share

  192. ERIKA HAYDU J, Abramson JS
    CAR T-cells in relapsed Burkitt lymphoma - a promising test drive in a rare disease.
    Leuk Lymphoma. 2022 Jul 20:1-2. doi: 10.1080/10428194.2022.2102625.
    >> Share

  193. ZHANG Q, Tao R, Li Z, Guo H, et al
    A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.
    Leuk Lymphoma. 2022 Jul 19:1-4. doi: 10.1080/10428194.2022.2074985.
    >> Share

  194. LI L, Yang C, Aruna, Zhou Q, et al
    Functional evaluation of various ICAM3 transcript variants in diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2022 Jul 18:1-10. doi: 10.1080/10428194.2022.2092861.
    >> Share

  195. SASSE S, Brockelmann PJ, Momotow J, Plutschow A, et al
    AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
    Leuk Lymphoma. 2022 Jul 18:1-8. doi: 10.1080/10428194.2022.2095623.
    >> Share

  196. YAMSHON S, Jing-Mei H
    Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target.
    Leuk Lymphoma. 2022 Jul 12:1-2. doi: 10.1080/10428194.2022.2092862.
    >> Share

  197. RAMALINGAM TR, Muthu A, Lakshmanan A, Narla S, et al
    Role of high acquisition flow cytometry in the detection of marrow involvement in patients with extramedullary B cell non-Hodgkins lymphoma: a comparison with marrow aspirate cytology, trephine biopsy, and PET.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2092858.
    >> Share

  198. PANAITE L, Wu QV, Voutsinas J, Mullane E, et al
    Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
    Leuk Lymphoma. 2022 Jul 9:1-5. doi: 10.1080/10428194.2022.2095632.
    >> Share

  199. BOMMIER C, Ruggiu M, Monegier A, Zucca E, et al
    Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials.
    Leuk Lymphoma. 2022;63:1544-1555.
    >> Share

  200. JUNG JM, Lee MY, Won CH, Chang SE, et al
    Hyperpigmented mycosis fungoides: a retrospective and comparative analysis with other subtypes of mycosis fungoides.
    Leuk Lymphoma. 2022;63:1598-1606.
    >> Share

    June 2022
  201. STUVER R, Lewis NE, Ewalt MD, Dogan A, et al
    First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone.
    Leuk Lymphoma. 2022 Jun 25:1-4. doi: 10.1080/10428194.2022.2092860.
    >> Share

  202. CHAHAL M, Hayden A, Savage KJ, Villa D, et al
    Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jun 24:1-4. doi: 10.1080/10428194.2022.2087071.
    >> Share

  203. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.
    >> Share

  204. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.
    >> Share

  205. QUALLS D, Kumar A, Epstein-Peterson ZD
    Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Leuk Lymphoma. 2022 Jun 15:1-13. doi: 10.1080/10428194.2022.2086244.
    >> Share

  206. ERIKSEN PRG, Clasen-Linde E, Brown PN, Haunstrup L, et al
    NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980-2017: a nationwide cohort study.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2087069.
    >> Share

  207. LEVY M, Dupuis J, Charpy C, Martin A, et al
    Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
    Leuk Lymphoma. 2022 Jun 10:1-7. doi: 10.1080/10428194.2022.2086248.
    >> Share

  208. TEO YH, Teo YN, Khoo LP, Chang EWY, et al
    Clinicopathological factors affecting prognosis in marginal zone lymphoma in Asian patients: a cohort study.
    Leuk Lymphoma. 2022 Jun 10:1-4. doi: 10.1080/10428194.2022.2086242.
    >> Share

  209. SEITTER SJ, McClelland PH, Ahlman MA, Goff SL, et al
    Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
    Leuk Lymphoma. 2022 Jun 9:1-5. doi: 10.1080/10428194.2022.2076853.
    >> Share

  210. ALLEN PB, Goyal S, Switchenko J, Tarabadkar E, et al
    Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
    Leuk Lymphoma. 2022 Jun 7:1-8. doi: 10.1080/10428194.2022.2081324.
    >> Share

  211. ARULOGUN SO, Abbasi MA, Pomplun S, O'Neill AT, et al
    Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenstrom Macroglobulinaemia.
    Leuk Lymphoma. 2022;63:1496-1499.
    >> Share

  212. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    >> Share

  213. GE J, Xia Y, Sun Z, Zhang L, et al
    Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
    Leuk Lymphoma. 2022;63:1369-1374.
    >> Share

    May 2022
  214. BERGER T, Geiger KR, Yeshurun M, Gafter-Gvili A, et al
    Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study.
    Leuk Lymphoma. 2022 May 28:1-8. doi: 10.1080/10428194.2022.2081325.
    >> Share

  215. TARIQ H
    Classic Hodgkin lymphoma cloaked in an intense sarcoid-like reaction.
    Leuk Lymphoma. 2022 May 27:1-4. doi: 10.1080/10428194.2022.2081848.
    >> Share

  216. MAN J, Wang H, Qian X, Chen L, et al
    TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study.
    Leuk Lymphoma. 2022 May 26:1-8. doi: 10.1080/10428194.2022.2076852.
    >> Share

  217. STRUSSMANN T, Wasch R, Scherer F, Mutter JA, et al
    A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin.
    Leuk Lymphoma. 2022 May 20:1-3. doi: 10.1080/10428194.2022.2074991.
    >> Share

  218. GORDON MJ, Sureda A, Westin JR
    Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Leuk Lymphoma. 2022 May 12:1-11. doi: 10.1080/10428194.2022.2068007.
    >> Share

  219. LO AC, Holloway CL, Savage KJ, Sehn LH, et al
    Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review.
    Leuk Lymphoma. 2022 May 5:1-4. doi: 10.1080/10428194.2022.2060505.
    >> Share

  220. EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
    Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
    Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
    >> Share

  221. LEBEL E, Goldschmidt N, Siegal T, Lossos A, et al
    Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
    Leuk Lymphoma. 2022 May 2:1-7. doi: 10.1080/10428194.2022.2064996.
    >> Share

    April 2022
  222. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    >> Share

  223. PHAM TM, Quy PN, Amin K, Walker E, et al
    Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
    Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
    >> Share

  224. PUCKRIN R, Chua N, Shafey M, Stewart DA, et al
    Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
    Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2068005.
    >> Share

  225. JUUL MB, Jelicic J, Anru PL, Engberg H, et al
    Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.
    Leuk Lymphoma. 2022 Apr 18:1-10. doi: 10.1080/10428194.2022.2064982.
    >> Share

  226. MAZIARZ RT, Yang H, Liu Q, Wang T, et al
    Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Leuk Lymphoma. 2022 Apr 14:1-11. doi: 10.1080/10428194.2022.2060503.
    >> Share

  227. SCHUSTER SJ, Zhang J, Yang H, Agarwal A, et al
    Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
    Leuk Lymphoma. 2022;63:845-854.
    >> Share

  228. DOI Y, Yokota T, Shibayama H, Matsumoto K, et al
    A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement.
    Leuk Lymphoma. 2022;63:1013-1015.
    >> Share

    March 2022
  229. LO AC, Major A, Super L, Appel B, et al
    Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW).
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053533.
    >> Share

  230. LIU L, Adlowitz DG, Rock P, Casulo C, et al
    Hypergammaglobulinemia as a presenting feature of Mantle cell lymphoma.
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2056177.
    >> Share

  231. WANG W, Mai B, Ali H, Chen L, et al
    Uncommon histiocyte-rich pseudotumor after chemotherapy in peripheral T-cell lymphoma.
    Leuk Lymphoma. 2022 Mar 31:1-3. doi: 10.1080/10428194.2022.2056176.
    >> Share

  232. RIBERA JM, Garcia O, Buendia-Urena B, Terol MJ, et al
    Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.
    Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053531.
    >> Share

  233. ZHOU J, Huang J, Xiao M, Wang Y, et al
    Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2022 Mar 11:1-9. doi: 10.1080/10428194.2022.2045595.
    >> Share

  234. BEN BAROUCH S, Bhella S, Kridel R, Kukreti V, et al
    Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.
    Leuk Lymphoma. 2022 Mar 9:1-8. doi: 10.1080/10428194.2022.2047674.
    >> Share

  235. KIM MS, Banerjee T, Chen A, Danilov A, et al
    A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma.
    Leuk Lymphoma. 2022 Mar 9:1-3. doi: 10.1080/10428194.2022.2045598.
    >> Share

  236. RODRIGUEZ-HERNANDEZ A, Giulino-Roth L
    The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience.
    Leuk Lymphoma. 2022 Mar 6:1-3. doi: 10.1080/10428194.2022.2045602.
    >> Share

  237. MOORE DC, Elmes JB, Strassels SA, Patel JN, et al
    Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.
    Leuk Lymphoma. 2022 Mar 6:1-2. doi: 10.1080/10428194.2022.2045601.
    >> Share

  238. FITZGERALD KN, Quesada AE, von Keudell G, Raj S, et al
    CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas.
    Leuk Lymphoma. 2022;63:751-754.
    >> Share

    February 2022
  239. SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
    >> Share

  240. WANG WJ, Omo-Ogboi AC, Rivera Rivera X, Moosvi AM, et al
    Bone primary, spindle cell variant of diffuse large B-cell lymphoma presenting in the femur from a Paget's disease patient.
    Leuk Lymphoma. 2022 Feb 27:1-3. doi: 10.1080/10428194.2022.2043305.
    >> Share

  241. MEHTA-SHAH N, Bartlett NL, Kahl B, Watkins MP, et al
    COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Leuk Lymphoma. 2022 Feb 27:1-5. doi: 10.1080/10428194.2022.2038377.
    >> Share

  242. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    >> Share

  243. BARR PM, Smith S, Roschewski M, O'Brien SM, et al
    Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 24:1-5. doi: 10.1080/10428194.2022.2043301.
    >> Share

  244. TAN JY, Qiu TY, Chiang J, Tan YH, et al
    Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
    Leuk Lymphoma. 2022 Feb 19:1-11. doi: 10.1080/10428194.2022.2027402.
    >> Share

  245. KARAKATSANIS S, Panitsas F, Arapaki M, Galopoulos D, et al
    Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance.
    Leuk Lymphoma. 2022 Feb 19:1-14. doi: 10.1080/10428194.2021.2010054.
    >> Share

  246. OGASAWARA M, Miyashita M, Yamagishi Y, Ota S, et al
    Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma.
    Leuk Lymphoma. 2022 Feb 15:1-5. doi: 10.1080/10428194.2022.2038371.
    >> Share

  247. CABIRTA A, Hidalgo-Gomez G, Marin-Niebla A, Gallur L, et al
    Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 7:1-4. doi: 10.1080/10428194.2022.2034158.
    >> Share

  248. BOND DA, Huang Y, Christian BA, Jaglowski S, et al
    A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 6:1-4. doi: 10.1080/10428194.2022.2034154.
    >> Share

  249. WANG A, Cirrone F, De Los Reyes FA, Papadopoulos J, et al
    High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
    Leuk Lymphoma. 2022 Feb 4:1-8. doi: 10.1080/10428194.2021.2024818.
    >> Share

  250. MELODY M, Gandhi S, Saunders H, Abdel-Rahman Z, et al
    Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.
    Leuk Lymphoma. 2022 Feb 3:1-6. doi: 10.1080/10428194.2022.2030475.
    >> Share

  251. BAJWA A, Huang Y, Li R, Denlinger N, et al
    Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2022 Feb 3:1-4. doi: 10.1080/10428194.2022.2032039.
    >> Share

  252. FISCHER T, Ni A, Bantilan KS, Soumerai JD, et al
    The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.
    Leuk Lymphoma. 2022 Feb 3:1-10. doi: 10.1080/10428194.2021.2010058.
    >> Share

  253. LUCIJANIC M, Huzjan Korunic R, Sedinic M, Kovacevic S, et al
    Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes.
    Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034160.
    >> Share

  254. NAKA R, Tada K, Kaneko H, Nagata O, et al
    Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (ritu
    Leuk Lymphoma. 2022 Feb 2:1-4. doi: 10.1080/10428194.2022.2032040.
    >> Share

  255. OLSZEWSKI AJ
    Ferritin, sex, and the wildfire of inflammation in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 2:1-3. doi: 10.1080/10428194.2022.2034161.
    >> Share

  256. BELLESI S, Sali M, Maiolo E, Pereyra Boza MDC, et al
    Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment.
    Leuk Lymphoma. 2022 Feb 1:1-5. doi: 10.1080/10428194.2022.2032042.
    >> Share

  257. KADDU-MULINDWA D, Lesan V, Berdel C, Stilgenbauer S, et al
    Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
    Leuk Lymphoma. 2022;63:326-334.
    >> Share

  258. RAMBURAN A, Kriel R, Govender D
    Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations.
    Leuk Lymphoma. 2022;63:370-376.
    >> Share

  259. DUELL J, Obr A, Augustin M, Endell J, et al
    CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
    Leuk Lymphoma. 2022;63:468-472.
    >> Share

    January 2022
  260. CAMUS V, Viennot M, Leveque E, Viailly PJ, et al
    Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.
    Leuk Lymphoma. 2022 Jan 25:1-11. doi: 10.1080/10428194.2021.2010060.
    >> Share

  261. FERRARI A, Arniani S, Crescenzi B, Ascani S, et al
    High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jan 19:1-7. doi: 10.1080/10428194.2021.2024821.
    >> Share

  262. KIM DW, Bukhari A, Lutfi F, Zafforoni F, et al
    Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2022 Jan 19:1-9. doi: 10.1080/10428194.2021.2024817.
    >> Share

  263. WADA F, Shimomura Y, Kamijo K, Yamashita D, et al
    Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.
    Leuk Lymphoma. 2022 Jan 19:1-4. doi: 10.1080/10428194.2021.2024820.
    >> Share

  264. PANAYIOTIDIS P, Tumyan G, Thieblemont C, Ptushkin VV, et al
    A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenstrom's macroglobulinemia.
    Leuk Lymphoma. 2022 Jan 19:1-12. doi: 10.1080/10428194.2021.2015765.
    >> Share

  265. CHOHAN K, Ansell SM
    Current salvage therapies in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jan 17:1-14. doi: 10.1080/10428194.2021.2024819.
    >> Share

  266. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    >> Share

  267. HEGER JM, Borchmann S
    Coming of age: the evolving role of circulating tumor DNA in malignant lymphoma.
    Leuk Lymphoma. 2022 Jan 12:1-3. doi: 10.1080/10428194.2022.2027404.
    >> Share

  268. HYBEL TE, Vase MO, Lauridsen KL, Enemark MB, et al
    CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus.
    Leuk Lymphoma. 2022 Jan 12:1-5. doi: 10.1080/10428194.2021.2023741.
    >> Share

  269. CIOS KJ, Huda TI, Eakins RA, Mihyu MM, et al
    Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2022 Jan 12:1-9. doi: 10.1080/10428194.2021.2020781.
    >> Share

  270. BURGER JA, Robak T, Demirkan F, Bairey O, et al
    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
    >> Share

  271. HENRY M, Buck S, Al-Qanber B, Gadgeel M, et al
    Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway.
    Leuk Lymphoma. 2022 Jan 8:1-8. doi: 10.1080/10428194.2021.2023744.
    >> Share

  272. ABRAHAO R, Brunson AM, Kahn JM, Li QW, et al
    Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.
    Leuk Lymphoma. 2022 Jan 6:1-11. doi: 10.1080/10428194.2021.2020775.
    >> Share

  273. MINSON A, Hofman M, Dickinson M
    A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse.
    Leuk Lymphoma. 2022;63:1-4.
    >> Share

  274. SEMCHENKOVA A, Zhogov V, Rudneva A, Potapenko L, et al
    Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas.
    Leuk Lymphoma. 2022;63:217-221.
    >> Share

  275. COSTA PA, Espejo-Freire AP, Fan KC, Albini TA, et al
    Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.
    Leuk Lymphoma. 2022;63:239-242.
    >> Share

  276. OTHMAN T, Moskoff BN, Esteghamat N, Hoeg RT, et al
    Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
    Leuk Lymphoma. 2022;63:231-234.
    >> Share

  277. ZHANG Y, Seminario-Vidal L, Varnadoe C, Lu Y, et al
    Clinical characteristics and prognostic factors of 70 patients with Sezary syndrome: a single-institutional experience at Moffitt cancer center.
    Leuk Lymphoma. 2022;63:109-116.
    >> Share

  278. PIROSA MC, Zhang L, Hitz F, Novak U, et al
    A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
    Leuk Lymphoma. 2022;63:117-123.
    >> Share

    December 2021
  279. GOUNI S, Strati P, Toruner G, Aradhya A, et al
    Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Dec 31:1-12. doi: 10.1080/10428194.2021.2020782.
    >> Share

  280. NAKAMURA N, Kanemura N, Lee S, Fujita K, et al
    Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2021 Dec 29:1-8. doi: 10.1080/10428194.2021.2020777.
    >> Share

  281. FORTUNY J, Plana E, Kaye JA
    Serum lipid trajectories in the years before a lymphoma diagnosis.
    Leuk Lymphoma. 2021 Dec 29:1-13. doi: 10.1080/10428194.2021.1992618.
    >> Share

  282. LEBEL E, Vainstein V, Ashkenazi M, Zimran E, et al
    Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
    Leuk Lymphoma. 2021 Dec 29:1-8. doi: 10.1080/10428194.2021.2018580.
    >> Share

  283. AMAADOR K, Vos JMI, Pals ST, Kraan W, et al
    Discriminating between Waldenstrom macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
    Leuk Lymphoma. 2021 Dec 27:1-10. doi: 10.1080/10428194.2021.2018584.
    >> Share

  284. ZHANG C, Mi L, Wu M, Liu W, et al
    Angioimmunoblastic T-cell lymphoma: treatment strategies and prognostic factors from a retrospective multicenter study in China.
    Leuk Lymphoma. 2021 Dec 27:1-8. doi: 10.1080/10428194.2021.2015586.
    >> Share

  285. GIEFING M, Gearhart MD, Schneider M, Overbeck B, et al
    Loss of function mutations of BCOR in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Dec 27:1-11. doi: 10.1080/10428194.2021.2015587.
    >> Share

  286. DE GROOT FA, de Haan LM, de Groen RAL, Heijmen L, et al
    Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.
    Leuk Lymphoma. 2021 Dec 21:1-5. doi: 10.1080/10428194.2021.2015589.
    >> Share

  287. TRABOLSI A, Alderuccio JP, Florindez J, Rodriguez G, et al
    Marginal zone lymphoma of the colon: case series from a single center and SEER data review.
    Leuk Lymphoma. 2021 Dec 19:1-7. doi: 10.1080/10428194.2021.2015766.
    >> Share

  288. KORSOS V, Vallee A, Rys R, Probst S, et al
    Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab.
    Leuk Lymphoma. 2021 Dec 16:1-5. doi: 10.1080/10428194.2021.2012571.
    >> Share

  289. KUMAR AJ, Chao CR, Rodday AM, Chang H, et al
    Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
    Leuk Lymphoma. 2021 Dec 10:1-8. doi: 10.1080/10428194.2021.2012660.
    >> Share

  290. JAIN S, Bakhshi S, Seth R, Verma N, et al
    Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01.
    Leuk Lymphoma. 2021 Dec 9:1-8. doi: 10.1080/10428194.2021.2012659.
    >> Share

  291. HALWANI AS, Panizo C, Isufi I, Herrera AF, et al
    Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
    Leuk Lymphoma. 2021 Dec 6:1-13. doi: 10.1080/10428194.2021.2010057.
    >> Share

  292. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    >> Share

  293. WITTE HM, Merz H, Bernd HW, Bauer A, et al
    Comparative analysis of international prognostic indices in gray-zone lymphoma.
    Leuk Lymphoma. 2021 Dec 2:1-9. doi: 10.1080/10428194.2021.2010067.
    >> Share

  294. GHAZZAUI N, Ferrad M, Issaoui H, Lecardeur S, et al
    HDAC recruitment in the IgH locus 3' regulatory region is different between mature B-cells and mature B-cell lymphomas.
    Leuk Lymphoma. 2021;62:3511-3515.
    >> Share

  295. STABER PB, Jurczak W, Greil R, Vucinic V, et al
    Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma. 2021;62:3440-3451.
    >> Share

  296. PEARSE WB, Petrich AM, Gordon LI, Karmali R, et al
    A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
    Leuk Lymphoma. 2021;62:3493-3500.
    >> Share

  297. WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
    Idelalisib immune-related toxicity is associated with improved treatment response.
    Leuk Lymphoma. 2021;62:2915-2920.
    >> Share

  298. MINSON A, Dickinson M
    Glofitamab CD20-TCB bispecific antibody.
    Leuk Lymphoma. 2021;62:3098-3108.
    >> Share

    November 2021
  299. MOZAS P, Rivero A, Rivas-Delgado A, Nadeu F, et al
    The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma.
    Leuk Lymphoma. 2021 Nov 29:1-8. doi: 10.1080/10428194.2021.2010064.
    >> Share

  300. LIU H, Li P, Zhao A, Lei W, et al
    Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.
    Leuk Lymphoma. 2021 Nov 28:1-4. doi: 10.1080/10428194.2021.2010062.
    >> Share

  301. GORDON MJ, Westin JR
    Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
    Leuk Lymphoma. 2021 Nov 28:1-11. doi: 10.1080/10428194.2021.2008383.
    >> Share

  302. PAK TK, Dixon BN, Buege MJ, Dao PH, et al
    Successful implementation of outpatient R +/- DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
    Leuk Lymphoma. 2021 Nov 16:1-9. doi: 10.1080/10428194.2021.2002318.
    >> Share

  303. SESHADRI MR, Melnick AM
    Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Nov 16:1-10. doi: 10.1080/10428194.2021.1999444.
    >> Share

  304. SHAH H, Jang H, Singh P, Kosti J, et al
    Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
    Leuk Lymphoma. 2021 Nov 15:1-8. doi: 10.1080/10428194.2021.2002322.
    >> Share

  305. SOLEIMANI A, Navarro A, Liu D, Herman SEM, et al
    CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
    Leuk Lymphoma. 2021 Nov 15:1-7. doi: 10.1080/10428194.2021.2002317.
    >> Share

  306. MELANI C, Wilson WH
    Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure.
    Leuk Lymphoma. 2021 Nov 11:1-3. doi: 10.1080/10428194.2021.2002323.
    >> Share

  307. REISS SN, Yerram P, Modelevsky L, Grommes C, et al
    Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
    Leuk Lymphoma. 2021 Nov 10:1-6. doi: 10.1080/10428194.2021.1998481.
    >> Share

  308. LI M, Ding N, Mi L, Shi Y, et al
    Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Leuk Lymphoma. 2021 Nov 9:1-10. doi: 10.1080/10428194.2021.1999441.
    >> Share

  309. MACKLIN-DOHERTY A, Jones M, Coulson P, Bruce C, et al
    Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment.
    Leuk Lymphoma. 2021 Nov 5:1-11. doi: 10.1080/10428194.2021.1999445.
    >> Share

  310. AVGERINOU G, Stefanaki K, Liapis K, Kostopoulos IV, et al
    Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.
    Leuk Lymphoma. 2021 Nov 2:1-11. doi: 10.1080/10428194.2021.1998480.
    >> Share

  311. LEVY A, Guidez S, Debiais C, Princet I, et al
    Waldenstrom macroglobulinemia and relationship to immune deficiency.
    Leuk Lymphoma. 2021;62:2665-2670.
    >> Share

    October 2021
  312. AUSSEDAT G, Maucort-Boulch D, Rey P, Safar V, et al
    Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
    Leuk Lymphoma. 2021 Oct 31:1-9. doi: 10.1080/10428194.2021.1998483.
    >> Share

  313. KIM HD, Cho H, Sohn BS, Park CS, et al
    Prognostic significance of serum beta2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.
    Leuk Lymphoma. 2021 Oct 26:1-7. doi: 10.1080/10428194.2021.1971220.
    >> Share

  314. MUSIU P, Quattrocchi L, Barberi W, Della Starza I, et al
    Donor cell derived mantle cell lymphoma in a HSCT sibling donor-recipient pair: intrinsic biological clock in lymphomagenesis.
    Leuk Lymphoma. 2021 Oct 25:1-4. doi: 10.1080/10428194.2021.1984456.
    >> Share

  315. IYER SG, Kuker R, Florindez JA, Saul E, et al
    A single-center analysis of patients with extranodal marginal zone lymphoma of the breast.
    Leuk Lymphoma. 2021 Oct 21:1-8. doi: 10.1080/10428194.2021.1992764.
    >> Share

  316. PUCKRIN R, Ghosh S, Peters A, Stewart D, et al
    Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities.
    Leuk Lymphoma. 2021 Oct 21:1-8. doi: 10.1080/10428194.2021.1992762.
    >> Share

  317. KONG D, Li Y, Fu C, Hou M, et al
    Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.
    Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992766.
    >> Share

  318. NG DZ, Lee CY, Lam WW, Tong AK, et al
    Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the DeltaSUVmax method.
    Leuk Lymphoma. 2021 Oct 19:1-4. doi: 10.1080/10428194.2021.1992624.
    >> Share

  319. YIN G, Man C, Cheng W, Gao X, et al
    The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2021 Oct 18:1-8. doi: 10.1080/10428194.2021.1992623.
    >> Share

  320. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    >> Share

  321. LEBLANC MR, Zimmerman S, LeBlanc TW, Bryant AL, et al
    Persistent fatigue among long-term non-Hodgkin lymphoma survivors.
    Leuk Lymphoma. 2021 Oct 6:1-9. doi: 10.1080/10428194.2021.1984450.
    >> Share

  322. MALFONA F, Testi AM, Moleti ML, Petrucci L, et al
    Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Leuk Lymphoma. 2021 Oct 6:1-4. doi: 10.1080/10428194.2021.1978091.
    >> Share

  323. TARIQ H, Pearse W, Moravek MR, Gao J, et al
    Refractory hemophagocytic lymphohistiocytosis in an adult patient with occult ALK-Positive anaplastic large cell lymphoma and a heterozygous MEFV mutation.
    Leuk Lymphoma. 2021 Oct 6:1-4. doi: 10.1080/10428194.2021.1984458.
    >> Share

  324. KLAIRMONT MM, Ward N
    Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes.
    Leuk Lymphoma. 2021 Oct 6:1-3. doi: 10.1080/10428194.2021.1984457.
    >> Share

  325. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.
    >> Share

  326. BRUMFIEL CM, Patel MH, DiCaudo DJ, Rosenthal AC, et al
    Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
    Leuk Lymphoma. 2021;62:2554-2555.
    >> Share

    September 2021
  327. ZHANG H, Liu M, Li Q, Lyu C, et al
    Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system.
    Leuk Lymphoma. 2021 Sep 29:1-9. doi: 10.1080/10428194.2021.1986216.
    >> Share

  328. SCHWAIGER BJ
    Closing the diagnostic gap: increasing recognition of bone mineral density loss after treatment of lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-2. doi: 10.1080/10428194.2021.1984461.
    >> Share

  329. ALDERUCCIO JP, Lossos IS
    NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
    Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
    >> Share

  330. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    >> Share

  331. SAWALHA Y, Radivoyevitch T, Jia X, Tullio K, et al
    The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2021 Sep 15:1-9. doi: 10.1080/10428194.2021.1978085.
    >> Share

  332. GONZALEZ DE VILLAMBROSIA S, Bastos M, Palanca JM, Cruz JG, et al
    BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.
    Leuk Lymphoma. 2021 Sep 11:1-8. doi: 10.1080/10428194.2021.1975189.
    >> Share

  333. KANAS G, Ge W, Quek RGW, Keeven K, et al
    Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.
    Leuk Lymphoma. 2021 Sep 11:1-10. doi: 10.1080/10428194.2021.1975188.
    >> Share

  334. HSU A, Kurt H, Zayac AS, Olszewski AJ, et al
    CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
    Leuk Lymphoma. 2021 Sep 1:1-12. doi: 10.1080/10428194.2021.1973670.
    >> Share

  335. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021;62:2161-2168.
    >> Share

  336. URYU H, Mishima Y, Tsuyama N, Yokoyama M, et al
    Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
    Leuk Lymphoma. 2021;62:2141-2150.
    >> Share

    August 2021
  337. LOPEZ-GUILLERMO A, Canales MA, Dlouhy I, Mercadal S, et al
    A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
    Leuk Lymphoma. 2021 Aug 30:1-8. doi: 10.1080/10428194.2021.1971216.
    >> Share

  338. HSU CH, Yang CS, Chen YJ, Lin TL, et al
    Primary neurolymphomatosis in extranodal natural killer/T-cell lymphoma diagnosed by skin biopsy.
    Leuk Lymphoma. 2021 Aug 27:1-3. doi: 10.1080/10428194.2021.1971221.
    >> Share

  339. CHERNG HJ, Chuang HH, Steiner R, Fayad L, et al
    A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 26:1-10. doi: 10.1080/10428194.2021.1971223.
    >> Share

  340. LANDSBURG DJ, Nasta SD, Gerson JN, Svoboda J, et al
    Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy.
    Leuk Lymphoma. 2021 Aug 26:1-4. doi: 10.1080/10428194.2021.1971224.
    >> Share

  341. HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
    Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.
    >> Share

  342. DENKER S, Bittner A, Frick M, Kase J, et al
    Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
    Leuk Lymphoma. 2021 Aug 20:1-9. doi: 10.1080/10428194.2021.1964024.
    >> Share

  343. ALDERUCCIO JP, Kuker RA, Barreto-Coelho P, Martinez BM, et al
    Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 20:1-11. doi: 10.1080/10428194.2021.1966786.
    >> Share

  344. AKYUZ N, Penas EMM, Janjetovic S, Loges S, et al
    Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case.
    Leuk Lymphoma. 2021 Aug 18:1-5. doi: 10.1080/10428194.2021.1966783.
    >> Share

  345. WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.
    >> Share

  346. AL ROWAIS F, Al Rabeh R, Al Mahasnah E, Al Shami A, et al
    Promising activity of single agent nivolumab followed by low-dose whole brain radiotherapy in isolated central nervous system relapse of Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Aug 12:1-4. doi: 10.1080/10428194.2021.1964025.
    >> Share

  347. BENDIG S, Walter W, Meggendorfer M, Bar C, et al
    Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 12:1-10. doi: 10.1080/10428194.2021.1964021.
    >> Share

  348. NASTOUPIL LJ, Neelapu SS, Davis RE, Samaniego F, et al
    Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K beta/delta in relapsed refractory B cell lymphoma.
    Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957874.
    >> Share

  349. JOHNSON WT, Kartan S, Sokol K, Nikbakht N, et al
    Clinical characteristics and outcomes of black patients with mycosis fungoides and Sezary syndrome: a subgroup analysis of the phase III MAVORIC trial.
    Leuk Lymphoma. 2021;62:1877-1883.
    >> Share

    July 2021
  350. PLATTEL WJ, Bergamasco A, Trinchese F, Gavini F, et al
    Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Jul 29:1-13. doi: 10.1080/10428194.2021.1957865.
    >> Share

  351. TOBIN JWD, Crothers A, Ma TE, Mollee P, et al
    A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.
    Leuk Lymphoma. 2021 Jul 29:1-9. doi: 10.1080/10428194.2021.1957866.
    >> Share

  352. HORWITZ S, Zinzani PL, Bagot M, Kim YH, et al
    Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Leuk Lymphoma. 2021 Jul 26:1-10. doi: 10.1080/10428194.2021.1953007.
    >> Share

  353. TAO Y, He X, Qin Y, Liu P, et al
    Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Jul 23:1-11. doi: 10.1080/10428194.2021.1953015.
    >> Share

  354. DURANI U, Ansell SM
    CD5+ diffuse large B-cell lymphoma: a narrative review.
    Leuk Lymphoma. 2021 Jul 21:1-9. doi: 10.1080/10428194.2021.1953010.
    >> Share

  355. BAEK GT, Mathis NJ, Perissinotti AJ, Marini BL, et al
    Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 15:1-9. doi: 10.1080/10428194.2021.1953014.
    >> Share

  356. SONG Y, Li J, Wang S, Zhou Z, et al
    The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jul 14:1-8. doi: 10.1080/10428194.2021.1948035.
    >> Share

  357. LAPIERRE L, Pericart S, Protin C, Borel C, et al
    Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 13:1-3. doi: 10.1080/10428194.2021.1950711.
    >> Share

  358. ALLIOUX F, Gandhi D, Vilque JP, Nganoa C, et al
    End-of-treatment (18)F-FDG PET/CT in diffuse large B cell lymphoma patients: DeltaSUV outperforms Deauville score.
    Leuk Lymphoma. 2021 Jul 5:1-9. doi: 10.1080/10428194.2021.1948028.
    >> Share

  359. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    >> Share

  360. MANSO R, Rodriguez-Perales S, Torres-Ruiz R, Santonja C, et al
    PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
    Leuk Lymphoma. 2021;62:1648-1656.
    >> Share

    June 2021
  361. MOU E, Falchi L, Sundaram V, Abramson JS, et al
    Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
    Leuk Lymphoma. 2021 Jun 26:1-9. doi: 10.1080/10428194.2021.1941936.
    >> Share

  362. XIAO Z, Mo Y, Long W, Li R, et al
    Value of baseline and end of chemotherapy (18)F-FDG PET/CT in pediatric patients with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 24:1-9. doi: 10.1080/10428194.2021.1941933.
    >> Share

  363. ELGAAFARY S, Lopez C, Nagel I, Vater I, et al
    Molecular characterization of Burkitt lymphoma in the breast or ovary.
    Leuk Lymphoma. 2021 Jun 24:1-10. doi: 10.1080/10428194.2021.1907374.
    >> Share

  364. OU YC, Tang Z, Novotny W, Cohen A, et al
    Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 Jun 23:1-13. doi: 10.1080/10428194.2021.1929961.
    >> Share

  365. CASTILLO JJ, Beltran BE, Malpica L, Marques-Piubelli ML, et al
    Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
    Leuk Lymphoma. 2021 Jun 21:1-9. doi: 10.1080/10428194.2021.1941929.
    >> Share

  366. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.
    >> Share

  367. MESSMER M, Wagner-Johnston N
    COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941939.
    >> Share

  368. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    >> Share

  369. KARALEXI MA, Pourtsidis A, Panagopoulou P, Moschovi M, et al
    Overall and event-free survival of childhood lymphoma in Greece: analysis of harmonized clinical data over a 24-year active registration period.
    Leuk Lymphoma. 2021 Jun 11:1-13. doi: 10.1080/10428194.2021.1907376.
    >> Share

  370. MOZESSOHN L, Zhang L, Odejide OO, Chen R, et al
    Prognostic value of disease risk score versus gait speed in older adults with lymphoma.
    Leuk Lymphoma. 2021 Jun 11:1-8. doi: 10.1080/10428194.2021.1938029.
    >> Share

  371. BRAM EDNERSSON S, Stern M, Fagman H, Nilsson-Ehle H, et al
    Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.
    Leuk Lymphoma. 2021 Jun 11:1-14. doi: 10.1080/10428194.2021.1913147.
    >> Share

  372. MINSON A, Dickinson M
    Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 9:1-3. doi: 10.1080/10428194.2021.1938033.
    >> Share

  373. SORIGUE M, Sancho JM
    The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 8:1-4. doi: 10.1080/10428194.2021.1929965.
    >> Share

  374. CHEN Q, Liu S, Zhang K, Yu B, et al
    Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1beta release in NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jun 3:1-9. doi: 10.1080/10428194.2021.1933472.
    >> Share

  375. RODRIGUES JM, Porwit A, Hassan M, Ek S, et al
    Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
    Leuk Lymphoma. 2021 Jun 3:1-11. doi: 10.1080/10428194.2021.1933480.
    >> Share

  376. TREVINO KM, Martin P, Saracino R, Leonard JP, et al
    Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis.
    Leuk Lymphoma. 2021;62:1370-1378.
    >> Share

  377. MOZAS P, Lopez-Guillermo A
    Response to: The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-2. doi: 10.1080/10428194.2021.1933482.
    >> Share

  378. ALVAREZ E, Le T, Kahn J, Winestone L, et al
    Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-7. doi: 10.1080/10428194.2021.1932873.
    >> Share

    May 2021
  379. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Primary thyroid lymphoma: survival analysis of SEER database (1995-2016).
    Leuk Lymphoma. 2021 May 27:1-4. doi: 10.1080/10428194.2021.1933479.
    >> Share

  380. ZHU X, Li W, Zhu J, Chen H, et al
    Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 25:1-9. doi: 10.1080/10428194.2021.1927017.
    >> Share

  381. PALOMBA ML, Jun MP, Lymp J, Nguyen A, et al
    Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686.
    >> Share

  382. BONZHEIM I, Quintanilla-Martinez L
    All activated signaling pathways lead to anaplastic large cell lymphoma (ALCL).
    Leuk Lymphoma. 2021 May 21:1-3. doi: 10.1080/10428194.2021.1924373.
    >> Share

  383. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.
    >> Share

  384. CHAPMAN J, Verdun RE, Lossos IS
    Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with MYC and MYC/BCL2 rearrangements, especially in germinal center cell-type tumors.
    Leuk Lymphoma. 2021 May 14:1-4. doi: 10.1080/10428194.2021.1927020.
    >> Share

  385. FAKHRI B, Yilmaz E, Gao F, Ambinder RF, et al
    Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 14:1-8. doi: 10.1080/10428194.2021.1927016.
    >> Share

  386. MACHAN S, Rodriguez M, Alonso-Alonso R, Manso R, et al
    Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes.
    Leuk Lymphoma. 2021 May 8:1-11. doi: 10.1080/10428194.2021.1901098.
    >> Share

  387. YANG J, Zhang Y, Yang P, Zhang X, et al
    A novel nomogram based on prognostic factors for predicting venous thrombosis risk in lymphoma patients.
    Leuk Lymphoma. 2021 May 8:1-9. doi: 10.1080/10428194.2021.1913149.
    >> Share

  388. GOYAL RK, Jain P, Nagar SP, Le H, et al
    Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 May 8:1-10. doi: 10.1080/10428194.2021.1919662.
    >> Share

  389. AL FEGHALI KA, Fang P, Gule-Monroe M, Milgrom S, et al
    Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
    Leuk Lymphoma. 2021 May 4:1-8. doi: 10.1080/10428194.2021.1919656.
    >> Share

  390. LANG N, Kuruvilla J
    Evolving management strategies for lymphomas during the COVID-19 pandemic.
    Leuk Lymphoma. 2021;62:1046-1056.
    >> Share

  391. WAGNER-JOHNSTON ND, Schuster SJ, deVos S, Salles G, et al
    Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Leuk Lymphoma. 2021;62:1077-1087.
    >> Share

  392. SEKAR A, Davids MS
    Idelalisib in indolent NHL - has it finally found its niche?
    Leuk Lymphoma. 2021;62:1029-1030.
    >> Share

    April 2021
  393. LUCIJANIC M, Korunic RH, Sedinic M, Kusec R, et al
    Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type.
    Leuk Lymphoma. 2021 Apr 28:1-4. doi: 10.1080/10428194.2021.1919667.
    >> Share

  394. CARPIO C, Iacoboni G, Villacampa G, Catala E, et al
    Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
    Leuk Lymphoma. 2021 Apr 24:1-4. doi: 10.1080/10428194.2021.1913141.
    >> Share

  395. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    >> Share

  396. WILSON WH, Phillips T, Popplewell L, de Vos S, et al
    Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-16. doi: 10.1080/10428194.2021.1907371.
    >> Share

  397. OLLIKAINEN RK, Kotkaranta PH, Kemppainen J, Teppo HR, et al
    Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-10. doi: 10.1080/10428194.2021.1913150.
    >> Share

    March 2021
  398. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    >> Share

  399. ISSA DE, Dinmohamed AG, Wondergem MJ, Blommestein HM, et al
    A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands.
    Leuk Lymphoma. 2021;62:549-559.
    >> Share

  400. BERNING P, Lenz G
    The role of PI3K inhibitors in the treatment of malignant lymphomas.
    Leuk Lymphoma. 2021;62:517-527.
    >> Share

    January 2021
  401. POLPRASERT C, Takeuchi Y, Makishima H, Wudhikarn K, et al
    Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.
    Leuk Lymphoma. 2021;62:95-103.
    >> Share

  402. VOORHEES TJ, Kannan KK, Galeotti J, Grover N, et al
    Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation.
    Leuk Lymphoma. 2021;62:86-94.
    >> Share

    October 2020
  403. CUI L, Gao C, Wang CJ, Zhao XX, et al
    Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Oct 15:1-9. doi: 10.1080/10428194.2020.1832668.
    >> Share

    July 2020
  404. ISUFI I, Seropian S, Gowda L, Wilson LD, et al
    Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Leuk Lymphoma. 2020 Jul 9:1-7. doi: 10.1080/10428194.2020.1790555.
    >> Share

    June 2020
  405. STRATI P, Ahmed MA, Nastoupil LJ, Feng L, et al
    Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
    Leuk Lymphoma. 2020;61:1380-1387.
    >> Share

    February 2020
  406. NARAZAKI T, Shiratsuchi M, Matsushima T, Tsuda M, et al
    Clinico-pathological characteristics of primary adrenal lymphomas - potential efficacy of autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Feb 10:1-3. doi: 10.1080/10428194.2020.1725507.
    >> Share

    January 2020
  407. PARIKH SA, Meacham PJ, Zent CS, Evans AG, et al
    Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.
    Leuk Lymphoma. 2020 Jan 11:1-15. doi: 10.1080/10428194.2019.1709830.
    >> Share

    September 2019
  408. MANCONI L, Coviello E, Canale F, Giannoni L, et al
    Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
    Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016